TAPIMMUNE INC COM USD0.001 (TPIV)

0.46
0.00 0.84
OTC
Prev Close 0.47
Open 0.46
Day Low/High 0.46 / 0.48
52 Wk Low/High 0.31 / 0.97
Volume 95.58K
Exchange OTC
Shares Outstanding 98.48B
Market Cap 46.38M
Div & Yield N.A. (N.A)

Latest News

TapImmune Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200

TapImmune Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200

Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials

TapImmune Appoints Frederick G. Wasserman To Its Board Of Directors

TapImmune Appoints Frederick G. Wasserman To Its Board Of Directors

Accomplished Financial Director & CFO of Public Companies

U.S. Food & Drug Administration Grants Orphan Drug Designation To TapImmune's TPIV 200 In The Treatment Of Ovarian Cancer

U.S. Food & Drug Administration Grants Orphan Drug Designation To TapImmune's TPIV 200 In The Treatment Of Ovarian Cancer

Company preparing for Phase II ovarian cancer trial based on positive data in Mayo Clinic Phase I trial

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters To Jacksonville Florida

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters To Jacksonville Florida

Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville

TapImmune Vaccine To Be Studied In A $13.3 Million U.S. Department Of Defense Grant To Mayo Clinic For Phase II Clinical Trial In Triple Negative Breast Cancer

TapImmune Vaccine To Be Studied In A $13.3 Million U.S. Department Of Defense Grant To Mayo Clinic For Phase II Clinical Trial In Triple Negative Breast Cancer

Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization

TapImmune Inc To Present At The SeeThruEquities Fall

TapImmune Inc To Present At The SeeThruEquities Fall

MicroCap Investors Conference on September 10, 2015

TapImmune Completes Transfer Of IND From The Mayo Clinic

TapImmune Completes Transfer Of IND From The Mayo Clinic

Significant Milestone Marks The Next Major Step in Beginning Phase 2 Trials in Cancer Using The Folate Receptor Alpha Peptide Vaccine Technology

TapImmune Appoints John N. Bonfiglio, Ph.D., To Its Board Of Directors

TapImmune Appoints John N. Bonfiglio, Ph.D., To Its Board Of Directors

Accomplished Biotech CEO is currently a Strategic Advisor to TapImmune

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A Folate Receptor Alpha Vaccine For Multiple Cancer Indications

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A Folate Receptor Alpha Vaccine For Multiple Cancer Indications

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials

From Our Partners